Tessera
Folgen

Alexis Rohou

@alexisrohou.bsky.social

CryoEM and structural biology methods, drug discovery. Also: Celtics, Camus, rocksteady, drum and bass. He, him, his. Disclosure: employee of Roche/Genentech (but expressing my personal views only).

752 Posts1684 Follower348 Folgt
Aaron Reichlin-Melnick@reichlinmelnick.bsky.social · last mo.

IMPORTANT to know that the vast majority of Haitians with TPS entered the country legally at ports of entry, not illegally. The majority have NEVER violated the law. The admin stripped their status by breaking the law, but today SCOTUS says courts can't do anything about that.

Chart shows Haitian migrant encounters by entry method, January 2021 to January 2025, showing that after mid-2022, nearly every entry was legal.
Aaron Reichlin-Melnick@reichlinmelnick.bsky.social · last mo.

BREAKING: The Supreme Court rules 6-3 in favor of the Trump admin on Temporary Protected Status, blocking the lawsuit on jurisdictional grounds, allowing DHS to strip over 350,000 people of legal status even though they utterly failed to follow the required legal procedures.

MULLIN v. DOE Syllabus that the termination of Haiti’s TPS designation violated the constitutional right to equal protection because it was motivated by race. The District Court granted interim relief, and a divided D. C. Circuit panel declined to issue a stay. The Government sought a stay and a writ of certiorari before judgment in both cases. This Court granted review, consolidated the cases, and deferred ruling on the stay applications. Held: 1. The TPS statute bars judicial review of non-constitutional claims. Pp. 12–18. (a) Section 1254a(b)(5)(A) provides that “[t]here is no judicial review of any determination of the [Secretary of Homeland Security] with respect to the designation, or termination or extension of a designation, of a foreign state.” The term “determination” may mean either an individual decision or the process leading to a decision. Under either understanding, §1254a(b)(5)(A) bars all of respondents’ non-constitutional claims. Further, the phrase “with respect to” “generally has a broadening effect, ensuring that the scope of a provision covers not only its subject but also matters relating to that subject.” Patel v. Garland, 596 U. S. 328, 339 (internal quotation marks omitted). Pp. 12– 13.
Laura Jedeed@laurajedeed.bsky.social · 2mo ago

When Trump went to war with Iran, I watched every speech anyone in the administration gave and made a chart of every reason given for going to war "Eliminate ballistic capability" was the #1 reason given: more even than preventing Iran from getting a nuclear weapon

Iran War Reasons Chart.xlsx

docs.google.com

Aaron Rupar@atrupar.com · 2mo ago

Trump endorses Iran having ballistic missiles: "I'm saying that if other countries have them, it's a little unfair for them not to have some"

Alexis Rohou@alexisrohou.bsky.social · 2mo ago

Great to see a formal treatment of the key problem of how to decide how many conformational states one should even attempt to reconstruct from cryoEM data.

@pilarcossio.bsky.social · 2mo ago

*Preprint Alert*: How do we measure resolution when biomolecules won't sit still? 🔬 Estimating it for a static cryo-EM reconstruction is standard. But what about a conformational ensemble? arxiv.org/abs/2606.14449 with the amazing henryhmattingly.bsky.social and @lukeevanshandle.bsky.social #cryoEM

Basil Greber@bjgreber.bsky.social · 2mo ago

This should be seen as Musk’s legacy. Not self-driving cars that crash or space rockets that keep exploding. This. All the reporting on Musk’s activities without highlighting the devastation caused by DOGE is extremely irresponsible. www.cnn.com/2026/02/04/w...

One year on from dismantling of USAID, study projects that global aid cuts could lead to 9.4 million deaths by 2030 | CNN

It’s been one year since the Trump administration dismantled the US Agency for International Development (USAID), with aid cuts leading to the closure of HIV clinics in South Africa, the termination o...

cnn.com

Chemjobber@chemjobber.bsky.social · 2mo ago

One more thing - this (the life sciences, and its associated products) is, in my opinion, the last place where America has/had the 'commanding heights' and Trump/Russell Vought is 100% trying to give that advantage away. Our children and grandchildren will be poorer and sicker for it.

Richard Ferro, MD MSc@richferro.com · 3mo ago

The groundbreaking research into the KRAS protein that led to the development of daraxonrasib was funded in part by the NIH. Public funding is the bedrock of pharmaceutical research.

Scott McGrath@smcgrath.phd · 3mo ago

Daraxonrasib is the first drug to substantially extend survival in pancreatic cancer trials. Median survival reached 13+ months compared to <7 months for chemo. It finally shuts down the "undruggable" KRAS protein, once called a greasy ball, using a novel molecular glue. #MedSky

Mark Peifer (He, him)@peiferlabunc.bsky.social · 3mo ago

While BioNtech & Moderna become household names because of their Covid vaccines, those emerged from different projects: finding ways to treat the most challenging cancers. They hypothesized that we could vaccinate patients against their own tumors, & evidence is mounting that they were right! 1/n 🧪

https://www.nature.com/articles/s41586-025-10004-2 Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC U. Sahin, M. Schmidt, E. Derhovanessian, A. Cortini, I. Vogler, T. Omokoko, E. Godehardt, S. Attig, S. Newrzela, J. Grützner, N. Bidmon, S. Bolte, S. Brachtendorf, T. Stuhlmann, D. Langer, D. Brüne, J. Blake, A. Feldner, H. Lindman, A. Schneeweiss, M. Eichbaum & Ö. Türeci Triple-negative breast cancer (TNBC) is frequently associated with metastatic relapse, even at an early stage1. Here we assessed an individualized neoantigen mRNA vaccine in 14 patients with TNBC following surgery and after neoadjuvant or adjuvant therapy. In peripheral blood of nearly all patients, high-magnitude, vaccine-induced, mostly de novo T cell responses to multiple neoantigens were detected that remained functional for several years. Characterization of individual patients revealed that a large proportion of these T cells developed into two subsets: a late-differentiated phenotype with markers indicative of ‘ready-to-act’ cytotoxic effector T cells, and T cells with a stem cell-like memory phenotype. Eleven patients remained relapse-free for up to six years post-vaccination. Recurrence occurred in three patients: the individual with the weakest vaccine-induced T cell response relapsed, but achieved complete remission on subsequent anti-PD-1 therapy; another patient had a tumour with low major histocompatibility complex (MHC) class I expression with MHC class I-deficient cells growing out under vaccination; and the third patient was BRCA-positive and had a recurrence from a genetically distinct primary tumour. These findings demonstrate the feasibility of individualized RNA vaccines in TNBC, document persistence of vaccine-induced, functional neoantigen-specific T cells and provide insights into possible immune escape mechanisms that will guide future approaches.